Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Africa

Lilly elects Prof Carolyn Bertozzi to board of directors

She brings oncology, inflammation and infection research expertise to the firm

- PMLiVE

FDA OKs Valeant’s psoriasis drug Siliq, with black box warning

Suicidal ideation labelling adds to challenge in rivalling Novartis’ Cosentyx and Lilly’s Taltz

- PMLiVE

Merck BACE inhibitor adds to litany of Alzheimer’s trial failures

Interim data shows “virtually no chance” of clinical success for verubecestat

Eli Lilly HQ

Lilly claims first place for JAK inhibitor Olumiant in EU

EMA approves once-daily rheumatoid arthritis drug ahead of Pfizer’s Xeljanz

- PMLiVE

Trump talks pricing and manufacturing with pharma

Heads of Celgene, Lilly, Merck & Co, Novartis and trade body PhRMA met at the White House

- PMLiVE

Novo Nordisk invests £115m in Oxford diabetes unit

But Danish pharma company admitted Brexit had made it a harder decision

- PMLiVE

AbbVie takes anti-tau drug into phase II for Alzheimer’s

Also testing antibody in rare condition PSP, for which FDA has awarded fast-track designation

- PMLiVE

J&J pondering future of diabetes device assets

Three diabetes care subsidiaries under review as firm forecasts measured 2017 sales

- PMLiVE

Real-world evidence

Companies are now recruiting high-level executives to lead well-resourced RWE teams as industry looks to reshape the future

Novo signs personalised digital health deal in diabetes

Will work with Glooko on jointly-developed and branded solutions

Eli Lilly HQ

Lilly streamlines and culls leadership roles

Merges Europe and emerging markets interests and expands diabetes and oncology

Eli Lilly HQ

Lilly nears EU approval of arthritis drug baricitinib

On course for early 2017 verdict, setting up challenge to Pfizer’s Xeljanz

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links